STOCK TITAN

Y-Mabs Therapeutics Inc - YMAB STOCK NEWS

Welcome to our dedicated news page for Y-Mabs Therapeutics (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Y-Mabs Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Y-Mabs Therapeutics's position in the market.

Rhea-AI Summary
Y-mAbs Therapeutics appoints Michael Rossi as President and CEO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
none
-
Rhea-AI Summary
Y-mAbs Therapeutics announces FDA clearance of IND application for CD38-SADA program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
News
Rhea-AI Summary
Y-mAbs announces publication of naxitamab-based chemo-immunotherapy study in patients with high-risk neuroblastoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Y-mAbs Therapeutics announces acceptance of four abstracts at SIOP Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
conferences
-
Rhea-AI Summary
Y-mAbs Therapeutics, Inc. (YMAB) reported record net product revenues of $20.8 million in Q2 2023, marking a 112% YoY growth. The company's management reiterated FY 2023 financial guidance, with cash and cash equivalents of $87.9 million as of June 30, 2023, expected to support operations into 2026. DANYELZA marketing authorization was granted in Brazil, and the company continues patient recruitment in the Phase I GD2-SADA trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.9%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
Y-Mabs Therapeutics Inc

Nasdaq:YMAB

YMAB Rankings

YMAB Stock Data

629.08M
25.36M
14.55%
66.36%
5.11%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About YMAB

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.